What is Leerink Partnrs' Forecast for BEAM FY2026 Earnings?

Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) - Equities researchers at Leerink Partnrs cut their FY2026 earnings per share (EPS) estimates for Beam Therapeutics in a report released on Thursday, July 17th. Leerink Partnrs analyst M. Foroohar now forecasts that the company will post earnings of ($4.35) per share for the year, down from their prior forecast of ($4.33). The consensus estimate for Beam Therapeutics' current full-year earnings is ($4.57) per share.

BEAM has been the topic of a number of other reports. Bank of America raised shares of Beam Therapeutics from a "neutral" rating to a "buy" rating and set a $42.00 price target on the stock in a research report on Friday, March 28th. Guggenheim dropped their price target on shares of Beam Therapeutics from $78.00 to $55.00 and set a "buy" rating for the company in a research report on Wednesday, May 7th. Barclays cut their price target on Beam Therapeutics from $31.00 to $25.00 and set an "equal weight" rating for the company in a research note on Wednesday, May 7th. Wells Fargo & Company dropped their price objective on Beam Therapeutics from $75.00 to $70.00 and set an "overweight" rating for the company in a report on Wednesday, May 7th. Finally, HC Wainwright reissued a "buy" rating and set a $80.00 target price on shares of Beam Therapeutics in a report on Monday, April 7th. Two equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Buy" and an average price target of $48.75.

Beam Therapeutics Stock Performance

BEAM opened at $20.75 on Monday. The stock has a fifty day moving average of $18.04 and a 200-day moving average of $21.50. The company has a market capitalization of $2.09 billion, a P/E ratio of -4.50 and a beta of 2.07. Beam Therapeutics has a fifty-two week low of $13.53 and a fifty-two week high of $35.25.

Beam Therapeutics (NASDAQ:BEAM - Get Free Report) last released its quarterly earnings results on Tuesday, May 6th. The company reported ($1.24) earnings per share for the quarter, missing the consensus estimate of ($1.11) by ($0.13). Beam Therapeutics had a negative return on equity of 44.24% and a negative net margin of 609.24%. The firm had revenue of $7.47 million for the quarter, compared to analyst estimates of $14.69 million. During the same period in the previous year, the business posted ($1.21) earnings per share. The business's revenue for the quarter was up 1.4% on a year-over-year basis.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. grew its holdings in shares of Beam Therapeutics by 16.4% during the 1st quarter. Vanguard Group Inc. now owns 8,871,292 shares of the company's stock valued at $173,256,000 after purchasing an additional 1,249,303 shares during the last quarter. ARK Investment Management LLC grew its stake in shares of Beam Therapeutics by 20.0% during the first quarter. ARK Investment Management LLC now owns 8,480,089 shares of the company's stock worth $165,616,000 after buying an additional 1,412,060 shares during the last quarter. Farallon Capital Management LLC increased its holdings in shares of Beam Therapeutics by 0.4% during the fourth quarter. Farallon Capital Management LLC now owns 8,239,123 shares of the company's stock worth $204,330,000 after buying an additional 31,000 shares in the last quarter. Nikko Asset Management Americas Inc. increased its holdings in shares of Beam Therapeutics by 7.9% during the first quarter. Nikko Asset Management Americas Inc. now owns 4,270,020 shares of the company's stock worth $83,265,000 after buying an additional 312,409 shares in the last quarter. Finally, Sumitomo Mitsui Trust Group Inc. lifted its stake in shares of Beam Therapeutics by 7.8% in the 1st quarter. Sumitomo Mitsui Trust Group Inc. now owns 4,266,871 shares of the company's stock valued at $83,332,000 after acquiring an additional 309,260 shares during the last quarter. Institutional investors and hedge funds own 99.68% of the company's stock.

About Beam Therapeutics

Beam Therapeutics Inc, a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.